Citations

Clear

15 citation(s) found for "Schwartz, Joseph".

Poor Mobilization and Plerixafor Use in Matched Related Peripheral Hematopoietic Progenitor Cell Donors
Draper, Nicole, Connelly‐Smith, Laura , Alquist, Caroline R. , Fernando, Leonor P. , Jones, Andrew R. , Schmidt, Amy E. , Harmon, Charles S., Lee, Esther , Linnik, Yevgeniy , Cooling, Laura , Godbey, Elizabeth A, Cooling, Laura , Godbey, Elizabeth A. , Schwartz, Joseph E. , Jones, Andrew, Harmon, Charles

Mayo Clinic

Journal of Clinical Apheresis | December 20, 2025 | Volume: 40 | Issue: 6 | Pages: No page available

10.1002/jca.70074 | PMID 41420827 Get It

ABSTRACT Plerixafor (PLX) is FDA approved for use in autologous peripheral blood stem cell donors but not in allogeneic donors. This study was completed by members of the ASFA HPC Donor Subcommittee to examine the incidence and characteristics of poor mobilizers (PM) among matched related donors (MRD), as well as factors associated with PLX use in MRD. Risks of poor mobilization in MRD were older age, especially donors older than 60 years, lower baseline platelet counts, and heavier recipients. PLX use in PM was low but safe, tripling the success rate for collection. This study adds evidence to the body of literature to support use of PLX in allogeneic donors who are PM.
Development of a Uniform Apheresis Case Report Form for Standardized Collection of Apheresis Data
Johnson, Andrew D., Szczepiorkowski, Zbigniew M. , Karam, Oliver , Nellis, Marianne E. , Schwartz, Joseph, Wu, Yanyun , Armendariz, Tomas , Burgstaler, Edwin A. , Collins, Laura , Geile, Kira, Pavenski, Katerina , Sanchez, Amber P. , Witt, Volker, Muthusamy, Amutha, Ramesh, Vidhyalakshmi , Thao, Mai See , Chlebeck, Therese M., Zantek, Nicole D. , Karam, Oliver , Armendariz, Tomas , Burgstaler, Edwin, Zantek, Nicole D , Balogun, Rasheed A. , Schneiderman, Jennifer , Winters, Jeffrey L. , Pavenski, Katerina , Pederson, Thomas

Mayo Clinic

Journal of Clinical Apheresis | October 18, 2024 | Volume: 39 | Issue: 5 | Pages: No page available

10.1002/jca.22146 | PMID 39420527 Get It

ABSTRACTApheresis is performed worldwide for an increasing number of indications. The development of common data elements (CDE) for apheresis related areas may facilitate conduct of new research, enhance quality initiatives including benchmarking, and improve patient care. This report describes the systematic development of the Uniform Apheresis Case Report Form (UACRF) as part of the Apheresis in the United States (ApheresUS) program. A consensus panel of 17 diverse experts in apheresis, related specialties, and electronic case report form (eCRF), and database development was assembled. The panel met via online conferencing from November 17, 2020 to December 1, 2021. A draft document was posted online for public comment from October 11, 2021 to November 10, 2021. Feedback was collected using an online survey tool. The consensus panel revised the UACRF. This version was converted to an eCRF with additional changes made to improve usability in this format. The final version of the UACRF was created on August 24, 2023. The UACRF contains 16 modules: procedure and subject eligibility, patient demographics, general procedure information, laboratory parameters, vascular access, common procedure elements, eight procedure specific modules (mononuclear cell collection and seven therapeutic modalities), outcomes, and site information. A total of 137 data elements were created, including 57 with one or more subelements. The UACRF is the first systematic attempt to develop CDE for therapeutic apheresis and white blood cell collections. Further validation of the UACRF is necessary to confirm the tool's ability to collect the relevant data elements and determine the usability of the form.
A multi‐institutional survey of apheresis services among institutions in the United States
Yurtsever, Nalan, Jacobs, Jeremy W. , Park, Yara A. , Lauro, Deisen, Torres, Sarina, Ward, Dawn C. , Stephens, Laura D. , Adkins, Brian D. , Yurtsever, Nalan , Stephens, Laura , Tormey, Christopher A , Adkins, Brian David , Jacobs, Jeremy W , Yurtsever, Nalan , Booth, Garrett S. , Schwartz, Joseph E. , Woo, Jennifer S. , Allen, Elizabeth S. , Tormey, Christopher A.

Mayo Clinic

Journal of Clinical Apheresis | July 9, 2024 | Volume: 39 | Issue: 4 | Pages: No page available

10.1002/jca.22138 | PMID 38979705 Get It

AbstractIntroductionApheresis practices in the United States (US) have not been comprehensively characterized to date. This study aimed to address this gap by evaluating apheresis therapy through a national survey.MethodsA multi‐institutional survey was conducted between April and July 2023. The survey, comprising 54 questions, focused on institutional demographics, procedures, equipment, staffing, training, and impacts of the Coronavirus Disease 2019 (COVID‐19) pandemic. Responses from 22 institutions, primarily academic medical centers, were analyzed.ResultsTherapeutic plasma exchange (TPE) was the most common procedure, followed by hematopoietic progenitor cell collection (HPC‐A) and red blood cell exchange (RCE). CAR‐T cell collections were widespread, with some institutions supporting over 30 protocols concurrently. Most sites used the Spectra Optia Apheresis System, were managed by a transfusion medicine service, and employed internal apheresis providers. Insufficient staffing levels, exacerbated by the COVID‐19 pandemic, were common and most often addressed using overtime.DiscussionThe survey highlighted the ubiquity of TPE, expanding cellular collections and staffing challenges. The role of apheresis in supporting cellular therapy, particularly in newly developing cell and gene therapies and clinical trials, was evident. Staffing issues during the pandemic emphasized the need for innovative recruitment strategies.ConclusionThis nationwide survey provides the most comprehensive analysis to date of apheresis practices in large US academic centers.
Obstetric and Newborn Weak D-Phenotype RBC Testing and Rh Immune Globulin Management Recommendations: Lessons From a Blinded Specimen-Testing Survey of 81 Transfusion Services
Ramsey, Glenn , Park, Yara A. , Eder, Anne F. , Bobr, Aleh , Karafin, Matthew S. , King, Karen E., Schwartz, Joseph, Szczepiorkowski, Zbigniew M. , Souers, Rhona J., Thomas, Lamont, Delaney, Meghan , Karp, Julie Katz , Pagano, Monica B.

Mayo Clinic

Archives of Pathology & Laboratory Medicine | April 29, 2022 | Volume: 147 | Issue: 1 | Pages: 71-78

10.5858/arpa.2021-0250-cp | PMID 35486492 Get It

Context.— Modern RHD genotyping can be used to determine when patients with serologic weak D phenotypes have RHD gene variants at risk for anti-D alloimmunization. However, serologic testing, RhD interpretations, and laboratory management of these patients are quite variable. Objective.— To obtain interlaboratory comparisons of serologic testing, RhD interpretations, Rh immune globulin (RhIG) management, fetomaternal hemorrhage testing, and RHD genotyping for weak D-reactive specimens. Design.— We devised an educational exercise in which 81 transfusion services supporting obstetrics performed tube-method RhD typing on 2 unknown red blood cell challenge specimens identified as (1) maternal and (2) newborn. Both specimens were from the same weak D-reactive donor. The exercise revealed how participants responded to these different clinical situations. Results.— Of reporting laboratories, 14% (11 of 80) obtained discrepant immediate-spin reactions on the 2 specimens. Nine different reporting terms were used to interpret weak D-reactive maternal RhD types to obstetricians. In laboratories obtaining negative maternal immediate-spin reactions, 28% (16 of 57) performed unwarranted antiglobulin testing, sometimes leading to recommendations against giving RhIG. To screen for excess fetomaternal hemorrhage after a weak D-reactive newborn, 47% (34 of 73) of reporting laboratories would have employed a contraindicated fetal rosette test, risking false-negative results and inadequate RhIG coverage. Sixty percent (44 of 73) of laboratories would obtain RHD genotyping in some or all cases. Conclusions.— For obstetric and neonatal patients with serologic weak D phenotypes, we found several critical problems in transfusion service laboratory practices. We provide recommendations for appropriate testing, consistent immunohematologic terminology, and RHD genotype–guided management of Rh immune globulin therapy and RBC transfusions.
Lack of defined apheresis collection criteria in publicly available CAR‐T cell clinical trial descriptions: Comprehensive review of over 600 studies
Thibodeaux, Suzanne R. , Aqui, Nicole A., Park, Yara A. , Su, Leon , Zubair, Abba C. , Liu, Hien , Su, Leon L , Zubair, Abba C , Schneiderman, Jennifer , Winters, Jeffrey L. , Schwartz, Joseph

Mayo Clinic

Journal of Clinical Apheresis | January 27, 2022 | Volume: 37 | Issue: 3 | Pages: 223-236

10.1002/jca.21964 | PMID 35085413 Get It

AbstractBackgroundChimeric antigen receptor T (CAR‐T) cell successes have encouraged continued clinical study. Apheresis collection of starting material for CAR‐T cell therapy product manufacturing is critical but described approaches suggest variability and clinical guidelines are currently lacking. The goal of this study was to gather and assess variability in apheresis collection descriptions in publicly available CAR T‐cell therapy clinical trials.Study designWe searched clinicaltrials.gov (a publicly available clinical trial database) for “chimeric antigen receptor T cells” on July 01, 2020 and studies accessed July 30, 2020‐August 15, 2020. Data collected included date posted, study characteristics, apheresis mentions (number, location, and context), laboratory parameters and transfusion allowances. Apheresis context was analyzed using a qualitative inductive approach of grounded theory method with open coding. Text was classified into 37 context codes, grouped into 12 categories, and then consolidated into patient, procedure, product, and miscellaneous themes.ResultsApheresis was mentioned 1044 times in 322 (51.9%) of 621 total studies. Laboratory parameters mentioned included white blood cells (100 studies), absolute neutrophil count (220 studies), absolute lymphocyte count (102 studies), CD3+ cell (38 studies), hemoglobin (233 studies, 54 studies specified transfusion allowance), and platelet (269 studies, 48 studies specified transfusion allowance).ConclusionsApheresis collection of CAR‐T cell products is not well‐defined in clinical study descriptions and the context is inconsistent. Laboratory parameters useful for apheresis collection are variably present and do not consistently align with current practices. Further exploration, and clinical guideline development will encourage alignment of apheresis collections for CAR‐T cell products.
Update to the ASFA guidelines on the use of therapeutic apheresis in ANCA‐associated vasculitis
Balogun, Rasheed A. , Sanchez, Amber P. , Klingel, Reinhard , Witt, Volker, Aqui, Nicole A., Meyer, Erin , Padmanabhan, Anand , Wu, Yanyun , Zantek, Nicole D. , Connelly‐Smith, Laura , Zantek, Nicole D , Connelly-Smith, Laura , Dunbar, Nancy M , Pham, Huy P. , Schneiderman, Jennifer , Schwartz, Joseph E. , Dunbar, Nancy M.

Mayo Clinic

Journal of Clinical Apheresis | August 8, 2020 | Volume: 35 | Issue: 5 | Pages: 493-499

10.1002/jca.21820 | PMID 32770558 Get It

AbstractSince 1986, the American Society for Apheresis (ASFA) has published practice guidelines on the use of therapeutic apheresis in the Journal of Clinical Apheresis (JCA) Special Issue. Since 2007, updated guidelines have been published every 3 years to reflect current evidence based apheresis practice with the most recent edition (8th) published in 2019. With each edition, the guidelines are reviewed and updated based on any newly published literature since the last review. The PEXIVAS study, an international, randomized controlled trial comparing therapeutic plasma exchange (TPE) vs no TPE and standard vs reduced dose steroid regimen on the primary composite outcome of end stage renal disease or death in patients with ANCA‐associated vasculitis (AAV), was published in February 2020. This study represents the largest study on the role of therapeutic apheresis in AAV published to date and prompted the JCA Special Issue Writing Committee to reassess the current AAV fact sheet for updates based on this newly available evidence. This interim fact sheet summarizes current ASFA recommendations for the evidence‐based use of therapeutic apheresis in AAV and supersedes the recommendations published in the 2019 guidelines.
The ABC's of disaster management: Managing apheresis operations during the SARS‐CoV‐2 pandemic
Vossoughi, Sarah , Burgstaler, Edwin A. , Burgstaler, Edwin A , Winters, Jeffrey L. , Schwartz, Joseph E.

Mayo Clinic

Journal of Clinical Apheresis | June 30, 2020 | Volume: 35 | Issue: 4 | Pages: 243-245

10.1002/jca.21803 | PMID 32604469 Get It

What's in Your CART? Clinical insights on challenges in mononuclear cell collection for CAR‐T therapy
Annen, Kyle , Zubair, Abba C. , Schwartz, E. von, Szczepiorkowski, Zbigniew M. , Zubair, Abba C , Schwartz, Eileen, Schwartz, Joseph E. , Annen, Kyle

Mayo Clinic

Journal of Clinical Apheresis | March 18, 2020 | Volume: 35 | Issue: 3 | Pages: 234-235

10.1002/jca.21776 | PMID 32186782 Get It

Therapeutic plasma exchange for neuromyelitis optica spectrum disorder: A multicenter retrospective study by the ASFA neurologic diseases subcommittee
Ipe, Tina S. , Fernando, Leonor P. , Gokhale, Amit , Johnson, Andrew D., Kim, Haewon C., Monis, Grace F., Mo, Yunchun D., Morgan, Shanna, Sanford, Kimberly , Schmidt, Amy E. , Wu, Yanyun , Yamada, Chisa , Wong, Edward C.C. , Webb, Jennifer , Wu, Yanyun , Yamada, Chisa , Ipe, Tina S , Raval, Jay S. , Jacquot, Cyril , Pagano, Monica B. , Pham, Huy P. , Schwartz, Joseph E. , Waldman, Amy , Winters, Jeffrey L.

Mayo Clinic

Journal of Clinical Apheresis | November 9, 2019 | Volume: 35 | Issue: 1 | Pages: 25-32

10.1002/jca.21754 | PMID 31705563 Get It

AbstractImportanceNeuromyelitis optica/neuromyelitis optica spectrum disorder patients' response to therapeutic plasma exchange (TPE) is currently incompletely characterized.ObjectiveOur study aims to understand the clinical status improvement of neuromyelitis optica/neuromyelitis optica spectrum disorder patients treated with TPE.Design, Setting, and ParticipantsThis is a multicenter retrospective study conducted between 1 January 2003 and 31 July 2017 at 13 US hospitals performing apheresis procedures. Subjects studied were diagnosed with neuromyelitis optica/neuromyelitis optica spectrum disorder who received TPE during presentation with acute disease.Main Outcomes and MeasuresThe primary outcome was clinical status improvement in patients treated with TPE. Secondary measures were procedural and patient characteristics associated with response to treatment.ResultsWe evaluated 114 patients from 13 institutions. There was a female predilection. The largest ethnic group affected was non‐Hispanic Caucasian. The average age of diagnosis was 43.1 years. The average time to diagnosis was 3.1 years. On average, five procedures were performed during each treatment series. The most commonly performed plasma volume exchange was 1.0 to 1.25 using 5% albumin as replacement fluid. Most patients (52%) did not require an additional course of TPE and noted “mild” to “moderate” clinical status improvement. Maximal symptom improvement appeared by the fourth or fifth TPE treatment.Conclusion and RelevanceTPE improved the clinical status of patients. Adults responded more favorably than children. Procedural characteristics, including number of TPEs, plasma volume exchanged, and replacement fluid used, were similar between institutions. TPE was well‐tolerated and had a low severe adverse event profile.
Report of the ASFA apheresis registry on muscle specific kinase antibody positive myasthenia gravis
Yamada, Chisa , Pham, Huy P. , Wu, Yanyun , Cooling, Laura , Kim, Haewon C., Morgan, Shanna, Wong, Edward C.C. , Winters, Jeffrey L. , Schwartz, Joseph E. , Pham, Huy P , Yamada, Chisa

Mayo Clinic

Journal of Clinical Apheresis | March 6, 2016 | Volume: 32 | Issue: 1 | Pages: 5-11

10.1002/jca.21454 | PMID 26946363 Get It

Background: Anti‐muscle specific kinase antibody positive (MuSK Ab) myasthenia gravis (MG) patients are known to have different clinical course compared to anti‐acetylcholine receptor Ab positive MG patients. Therapeutic plasma exchange (TPE) has been reported to be effective; however, little is known of the response and of TPE procedural information. An ASFA Apheresis Registry was developed to analyze those data. Methods: The study collected detailed de‐identified patient data, TPE procedures, and treatment outcome/complications. Collected data was described in aggregate. Results: A total of 15 MuSK Ab MG patients with exacerbation of MG symptoms, 13 females/2 males, median age 44, were investigated. Thirty TPE courses (median 5 procedures/course, total 145 procedures) were evaluated. All TPE procedures were performed with citrate anticoagulation, 1 − 1.25 plasma volume exchange in 100% fluid balance, and 90% of courses used only albumin as replacement. Calcium was added to albumin or given orally as needed. TPE was performed every other day in 55% of courses. Adverse events occurred in 3.4% of procedures. Ten patients (67%) experienced relapses within a median of 7 weeks. Objective symptoms were resolved in more than 75% of courses. Overall subjective improvement rates were 94.1%/93.3% after 3/4 TPE procedures, respectively. Thirty‐one percent of patients responded poorly with minimal recovery. Conclusion: Overall subjective improvement was seen up to 94% of patients after one course of TPE. Some patients were poor‐responders. Five TPE may be adequate for initial course with additional TPE as needed. Based upon this preliminary data, we will modify our future data collection. J. Clin. Apheresis 32:5–11, 2017. © 2016 Wiley Periodicals, Inc.